Bridgeway Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$136K Sell
150,000
-17,900
-11% -$16.2K ﹤0.01% 1027
2025
Q1
$75.8K Sell
167,900
-250,000
-60% -$113K ﹤0.01% 1083
2024
Q4
$210K Sell
417,900
-338,866
-45% -$170K ﹤0.01% 997
2024
Q3
$685K Buy
756,766
+75,000
+11% +$67.9K 0.01% 779
2024
Q2
$680K Hold
681,766
0.02% 792
2024
Q1
$1.01M Sell
681,766
-100,000
-13% -$148K 0.02% 741
2023
Q4
$852K Hold
781,766
0.02% 794
2023
Q3
$922K Hold
781,766
0.02% 727
2023
Q2
$1.1M Hold
781,766
0.03% 706
2023
Q1
$1.17M Hold
781,766
0.03% 690
2022
Q4
$915K Buy
781,766
+540,100
+223% +$632K 0.02% 748
2022
Q3
$273K Sell
241,666
-152,700
-39% -$172K 0.01% 1069
2022
Q2
$623K Buy
394,366
+379,700
+2,589% +$600K 0.01% 833
2022
Q1
$23K Sell
14,666
-202,600
-93% -$318K ﹤0.01% 1303
2021
Q4
$532K Sell
217,266
-11,000
-5% -$26.9K 0.01% 968
2021
Q3
$575K Sell
228,266
-368,161
-62% -$927K 0.01% 993
2021
Q2
$1.7M Sell
596,427
-46,712
-7% -$133K 0.03% 684
2021
Q1
$1.51M Sell
643,139
-37,700
-6% -$88.6K 0.03% 717
2020
Q4
$1.2M Buy
680,839
+96,300
+16% +$169K 0.03% 709
2020
Q3
$547K Buy
584,539
+126,479
+28% +$118K 0.01% 852
2020
Q2
$399K Sell
458,060
-70,979
-13% -$61.8K 0.01% 935
2020
Q1
$438K Hold
529,039
0.01% 810
2019
Q4
$471K Hold
529,039
0.01% 1016
2019
Q3
$518K Hold
529,039
0.01% 947
2019
Q2
$582K Hold
529,039
0.01% 929
2019
Q1
$693K Buy
529,039
+288,339
+120% +$378K 0.01% 896
2018
Q4
$220K Buy
240,700
+22,730
+10% +$20.8K ﹤0.01% 1201
2018
Q3
$448K Buy
+217,970
New +$448K ﹤0.01% 1171
2014
Q4
Sell
-153,390
Closed -$389K 1482
2014
Q3
$389K Hold
153,390
0.01% 1193
2014
Q2
$378K Hold
153,390
0.01% 1202
2014
Q1
$407K Hold
153,390
0.01% 1165
2013
Q4
$446K Hold
153,390
0.01% 1095
2013
Q3
$470K Hold
153,390
0.02% 1068
2013
Q2
$490K Buy
+153,390
New +$490K 0.02% 952